[meta-analysis of Serum Tumor Markers in Lung Cancer]
Overview
Pulmonary Medicine
Authors
Affiliations
Background And Objective: the detection of serum tumor markers is of great value for early diagnosis of lung cancer. The aim of this study is to summarize the clinic significance characteristics of serum markers contributing to the detection of lung cancer.
Methods: references about serum markers of lung cancer were estimated using meta-analysis method. 712 references which included more than 20 cases, 20 controls, the serum markers of 52 832 patients with malignancies and 32 037 patients as controls were evaluated.
Results: overall the detection of 13 markers play a significant part in lung cancer diagnosis. The sensitivity of CEA, CA125, CYFRA21-1, TPA, SCCAg, DKK1, NSE, ProGRP in the patients' serum with lung cancer were 47.50%, 50.11%, 57.00%, 50.93%, 49.00%, 69.50%, 39.73%, 51.48% and the specificity were 92.34%, 80.19%, 90.16%, 88.41%, 91.07%, 92.20%, 89.11%, 94.89%. In the combined analysis of tumor markers: the sensitivity, specificity of NSE+ProGRP were 88.90% and 72.82% in diagnosis of small cell lung cancer, respectively. In diagnosis of squamous corcinoma, the sensitivity and specificity of TSGF+SCCAg+CYFRA21-1 were 95.30% and 74.20%. The the sensitivity and specificity of CA153+Ferrtin+CEA were 91.90% and 44.00% in diagnosis of lung cancer.
Conclusions: although the assay of tumor markers in serum is useful for diagnosis of early lung cancer, the sensitivity and specificity are low. Combined detection of these tumor markers could increase sensitivity and specificity.
Jiang W, Wu J, Lin X, Chen Z, Lin L, Yang J Clin Med Insights Oncol. 2024; 18:11795549241231568.
PMID: 38525298 PMC: 10960340. DOI: 10.1177/11795549241231568.
Identification of key candidate tumor biomarkers in non-small-cell lung cancer by analysis.
Chen W, Zhu S, Zhang Y, Xiao J, Tian D Oncol Lett. 2020; 19(1):1008-1016.
PMID: 31897214 PMC: 6924182. DOI: 10.3892/ol.2019.11169.
[Expression and Clinical Significance of MAGE-C2 in Lung Adenocarcinoma].
Guo K, Lu M, Xu P, Li H Zhongguo Fei Ai Za Zhi. 2016; 19(2):88-92.
PMID: 26903162 PMC: 6015139. DOI: 10.3779/j.issn.1009-3419.2016.02.09.
Zhang H, Li H, Yu Z, Yu X, Guo K Thorac Cancer. 2016; 5(4):275-80.
PMID: 26767013 PMC: 4704350. DOI: 10.1111/1759-7714.12087.
Diagnostic value of circulating microRNAs for lung cancer: a meta-analysis.
Shen Y, Wang T, Yang T, Hu Q, Wan C, Chen L Genet Test Mol Biomarkers. 2013; 17(5):359-66.
PMID: 23387316 PMC: 3634145. DOI: 10.1089/gtmb.2012.0370.